Communiqués Northwest Biotherapeutics, Inc.

Actions

NWBO

US66737P6007

Recherche biotechnologique et médicale

Temps Différé OTC Markets Autres places de cotation 20:31:06 16/07/2026			Varia. 5j.	Varia. 1 janv.
0,1528 ^USD	-7,67%		-14,11%	-33,22%

08/07	Northwest Biotherapeutics présente des données de survie actualisées de l'essai de phase III du DCVax-L contre le glioblastome	CI
15/05	Northwest Biotherapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

08/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
02/07	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
15/05	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
30/04	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
21/04	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR
20/11	Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility	PR
14/11	Northwest Biotherapeutics: Q3 Earnings Snapshot	AQ
24/10/25	Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed	PR
27/08/25	Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.	PR
18/08/25	Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	PR
15/08/25	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
11/06/25	Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments	PR
16/05/25	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
26/12/24	Northwest Biotherapeutics : Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing Form 8 K	PU
26/12/24	Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing	PR
13/11/24	Northwest Biotherapeutics: Q3 Earnings Snapshot	AQ
09/08/24	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
02/08/24	Northwest Biotherapeutics : Regulation FD Disclosure Form 8 K	PU
03/07/24	Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities	PR
17/06/24	Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property	PR
10/05/24	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
06/02/24	Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification	PR
22/12/23	Northwest Biotherapeutics announces that a Marketing Authorization Application has been submitted to the UK MHRA for DCVax-L for Glioblastoma	AQ
21/12/23	Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma	PR
22/11/23	Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application	PR